Drug design, development and therapy · 2026
The Effect of Esketamine on Peripheral Vascular Resistance in Elderly Patients During Anesthesia Induction: A Single-Center, Double-Blind, Prospective, Randomized Controlled Study.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Jingjing, Gao Yu, Jing Kailun, Lu Hanjie, Cao Yunlong, Chen Xiaolong, Wang Hong, Song Xiaoyang, Gan Guosheng, Tan Shigang
Аннотация
PURPOSE: To investigate the effect of esketamine on peripheral vascular resistance in elderly patients during anesthesia induction.
PATIENTS AND METHODS: Eighty elderly patients undergoing elective surgery were randomly assigned to two groups (n=40 each): the esketamine group (Group A) received esketamine 0.3 mg/kg, while the control group (Group B) received an equal volume of normal saline. Both groups received the same standard anesthesia induction (etomidate, sufentanil, rocuronium). Hemodynamic parameters (SBP, DBP, MAP, HR) and peripheral vascular resistance assessed by the snuffbox radial artery resistance index (SBRI) were recorded at seven time points: before induction (T1), 1 min (T2) and 5 min (T3) after induction, during intubation (T4), and 1 min (T5), 5 min (T6), and 10 min (T7) after intubation. Adverse events during induction and postoperative recovery were also documented. This double-blind study masked drug administration and outcome assessment.
RESULTS: No significant baseline differences existed between groups (P>0.05). MAP in Group A was significantly higher than in Group B at T2-T7 (P<0.05). SBRI in Group A was significantly higher than in Group B at T2 and T3 (P<0.05), but not at T4-T7. Group A had lower incidences of hypotension (14.3% vs 56.4%), muscle tremor (8.6% vs 33.3%), and vasoactive drug use (5.7% vs 38.5%) (all P<0.05). No significant differences were observed in other adverse events or postoperative recovery scores. Postoperative VAS pain score was slightly lower in Group A (P<0.05).
CONCLUSION: Esketamine used during anesthesia induction shows promise in mitigating early-phase blood pressure decline, increasing peripheral vascular resistance (T2-T3), maintaining hemodynamic stability, and reducing hypotension, muscle tremor, and vasoactive drug use in elderly patients, without compromising recovery.
PATIENTS AND METHODS: Eighty elderly patients undergoing elective surgery were randomly assigned to two groups (n=40 each): the esketamine group (Group A) received esketamine 0.3 mg/kg, while the control group (Group B) received an equal volume of normal saline. Both groups received the same standard anesthesia induction (etomidate, sufentanil, rocuronium). Hemodynamic parameters (SBP, DBP, MAP, HR) and peripheral vascular resistance assessed by the snuffbox radial artery resistance index (SBRI) were recorded at seven time points: before induction (T1), 1 min (T2) and 5 min (T3) after induction, during intubation (T4), and 1 min (T5), 5 min (T6), and 10 min (T7) after intubation. Adverse events during induction and postoperative recovery were also documented. This double-blind study masked drug administration and outcome assessment.
RESULTS: No significant baseline differences existed between groups (P>0.05). MAP in Group A was significantly higher than in Group B at T2-T7 (P<0.05). SBRI in Group A was significantly higher than in Group B at T2 and T3 (P<0.05), but not at T4-T7. Group A had lower incidences of hypotension (14.3% vs 56.4%), muscle tremor (8.6% vs 33.3%), and vasoactive drug use (5.7% vs 38.5%) (all P<0.05). No significant differences were observed in other adverse events or postoperative recovery scores. Postoperative VAS pain score was slightly lower in Group A (P<0.05).
CONCLUSION: Esketamine used during anesthesia induction shows promise in mitigating early-phase blood pressure decline, increasing peripheral vascular resistance (T2-T3), maintaining hemodynamic stability, and reducing hypotension, muscle tremor, and vasoactive drug use in elderly patients, without compromising recovery.